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RESEARCH ARTICLE

Open Access

Microwave imaging for neoadjuvant
chemotherapy monitoring: initial clinical
experience
Paul M Meaney1*, Peter A Kaufman2, Lori S Muffly2, Michael Click3, Stephen P Poplack3, Wendy A Wells4,
Gary N Schwartz2, Roberta M di Florio-Alexander3, Tor D Tosteson5, Zhongze Li5, Shireen D Geimer6,
Margaret W Fanning7, Tian Zhou8, Neil R Epstein1 and Keith D Paulsen1

Abstract
Introduction: Microwave tomography recovers images of tissue dielectric properties, which appear to be specific
for breast cancer, with low-cost technology that does not present an exposure risk, suggesting the modality may
be a good candidate for monitoring neoadjuvant chemotherapy.
Methods: Eight patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer were imaged
longitudinally five to eight times during the course of treatment. At the start of therapy, regions of interest (ROIs)
were identified from contrast-enhanced magnetic resonance imaging studies. During subsequent microwave
examinations, subjects were positioned with their breasts pendant in a coupling fluid and surrounded by an
immersed antenna array. Microwave property values were extracted from the ROIs through an automated
procedure and statistical analyses were performed to assess short term (30 days) and longer term (four to six
months) dielectric property changes.
Results: Two patient cases (one complete and one partial response) are presented in detail and demonstrate
changes in microwave properties commensurate with the degree of treatment response observed pathologically.
Normalized mean conductivity in ROIs from patients with complete pathological responses was significantly
different from that of partial responders (P value = 0.004). In addition, the normalized conductivity measure also
correlated well with complete pathological response at 30 days (P value = 0.002).
Conclusions: These preliminary findings suggest that both early and late conductivity property changes correlate
well with overall treatment response to neoadjuvant therapy in locally advanced breast cancer. This result is
consistent with earlier clinical outcomes that lesion conductivity is specific to differentiating breast cancer from
benign lesions and normal tissue.

Introduction
Neoadjuvant chemotherapy (NCT) for breast cancer has
become an increasingly important treatment option [1]
that offers potential therapeutic advantages. Various clinical trials have demonstrated that treatment response,
including tumor shrinkage, leads to substantial downstaging of disease which in turn allows for increased use of
more limited surgery [1]. In such cases, breast conservation
* Correspondence: paul.meaney@dartmouth.edu
1
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strategies such as lumpectomies and radiotherapy can be
used instead of more comprehensive radical mastectomies
[2]. By monitoring the patient’s response to systemic
therapy before tumor resection, prediction of longer term
prognosis or identification of the need for additional or
alternative treatment may be possible. Data have suggested
that patients receiving neoadjuvant therapy with pathologic
complete response have better survival outcomes [1,3].
While NCT is emerging as a promising treatment strategy for locally advanced breast cancer, deploying monitoring methods during the course of therapy is important
for making further advances. Magnetic resonance (MR)

© 2013 Meaney et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
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and fluorodeoxyglucose positron emission tomography
(FDG PET) have been evaluated in several clinical trials
and have proven useful in this setting, but both also
come at considerable cost and inconvenience [3-8].
Conventional breast imaging modalities, such as ultrasound and mammography, have been disappointing in
detecting the extent of residual disease during treatment
[9]. Studies have also been conducted using Doppler
ultrasonography, diffuse optical spectroscopy and tomography and scintimammography [10-13]. Assessing
tumor shrinkage by clinical breast examination is possible as well but is poorly correlated with treatment
response [1].
Microwave imaging is in the early stages of clinical evaluation and most of the work has focused on breast tumor
detection. Impressive technical developments based on
active microwave radar concepts have been reported
[14-18]. Passive microwave radiometry has also been
investigated [19-21]. However, only a modest number of
clinical microwave tomographic (MT) breast examinations
have been conducted [22-24]. Our early clinical experience
with MT has demonstrated statistically significant differences in the electrical conductivity of breast tumors
greater than 1 cm in diameter relative to the normal breast
and other benign abnormalities [25]. We have also shown
strong associations between whole breast radiographic
density designations as well as focal patterns of dense
fibroglandular tissue and the imaged microwave property
distributions [26].
We are currently evaluating women undergoing NCT
for the treatment of locally-advanced breast cancer with
MT performed at regular intervals from the start of treatment to the time of surgery. In the following sections, we
describe the methods used in the study related to patient
recruiting, imaging modalities, pathology and image analysis. In the Results section, we examine two cases in detail
(one complete responder and a second non-responder) to
provide an appreciation of the information contained in
the images and their progression during treatment. In
addition, we also include a representative sequence of
images from the contralateral breast for one patient during
the course of treatment as an example of the more limited
changes observed in the non-cancerous breast. Finally, we
statistically analyze the results for the eight patients in this
study.

Materials and methods
Patient recruiting

The microwave imaging study was Health Insurance Portability and Accountability Act (HIPAA) compliant and
approved by the institutional review board (IRB) at Dartmouth. These experiments comply with the current laws
of the United States of America. All patients provided
written informed consent and were compensated for their
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participation. Eight women enrolled in a pilot study,
successfully completed their treatment and corresponding
series of MT examinations. These patients proceed
through the prescribed chemotherapy regimen until surgery as part of standard-of-care breast cancer management. In most cases, MR images of both breasts were
acquired just prior to therapy and again after treatment
but before surgery (one case was followed with ultrasound
examinations). After surgery, all breast tissue was analyzed
in Surgical Pathology at Dartmouth-Hitchcock Medical
Center (DHMC) to document the extent of treatment
response. Table 1 summarizes the patient information for
the subjects enrolled in this pilot stage of our study.
Microwave Tomography

For each TM session, patients lie prone on a padded
table with one breast pendant through an aperture into
a coupling liquid. An array of monopole antennas with
fixed radial positions on a 15.2 cm diameter circle are
moved up from the base of the imaging tank into a
position surrounding the breast close to the chestwall.
Data are acquired over multiple frequencies (700 to
1,700 MHz in 200 MHz increments) with each antenna
sequentially acting as the transmitter and the remaining
complement serving as receivers for a total of 240 (16
transmitters × 15 receivers) measurements at each frequency. The antennas are subsequently moved to six
lower positions in 1 cm increments (or less depending
on the overall breast length) where the data acquisition
sequence is repeated to provide coverage of the breast.
After data acquisition is completed on one breast, the
patient is repositioned and the contralateral breast is
imaged under the same protocol for a total examination
time of approximately 15 minutes (approximately 5 minutes of data acquisition time per breast and 5 minutes
for breast positioning).
We utilized either 80% or 86% glycerin coupling baths
for patient examinations. At the first pre-therapy imaging
session, baseline data were acquired with both baths for
each patient. We determined the optimal bath for a given
subject by evaluating the measured data and image quality
from both acquisitions [26]. Given the variability of the
average microwave properties of the breast, especially with
respect to its density and the patient’s age, we compared
the recovered images empirically on a patient-by-patient
basis in order to determine the best mixture for future
examinations [24]. Once the bath of choice was established, the liquid was recycled and used only for the subsequent examinations of that individual patient.
Permittivity and conductivity images were reconstructed post-examination for associated frequencies and
antenna positions. Each image was processed in less than
two minutes on a Dell Blade workstation using our twodimensional finite difference time domain (FDTD)-based
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Table 1 Summary of patient data
Study
Number

Breast
Density

Size
(cm)

Pathology

Exams Treatment

1

SC

7 × 6.5

IDC, ER+/PR-/HER2neu+

7

AC2/paclitaxel
trastuzumab

Yes (MRI)

pCR

2

HD

5×3

IDC, ER-/PR-/HER2neu-

7

paclitaxel tocosol

No substantial response
(MRI)

pPR2

3

SC

4×4

IDC, ER-/PR-/HER2neu-

5

TAC3

Yes (MRI)

pCR

2

Radiographic Response Pathologic
Response

4

HD

5×5

IDC, ER+/PR+/HER2neu+

5

AC /paclitaxel
trastuzumab

Yes (MRI)

pCR

5

ED

8×7

IDC, ER+/PR+/HER2neu-

10

AC2/paclitaxel

No substantial response
(MRI)

pPR4

6

HD

1×1

IDC, ER equivocal/PR-/
HER2neu+

8

Taxol/FEC/Herceptin

Yes (MRI)

pCR

7

ED

10 × 9

IDC, ER-/PR-/HER2neu+

4

TAC3

Yes (MRI)

pPR1

5

3

No substantial response
(MRI)

pPR3

8

HD

4×4

IDC, ER+/PR+/HER2neu+

TAC

AC2, doxorubicin and cyclophosphamide; ED, extremely dense; ER, estrogen receptor; HD, heterogeneously dense; HER2-neu, human epidermal growth factor
receptor 2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; pPR1, near total treatment effect (< 10% of tumor remaining) [32]; pPR2, evidence of
response to therapy but with 10% to 50% of tumor remaining [32]; pPR3, evidence of response to therapy but with > 50% < 90% of tumor remaining [32]; pPR4,
minimal evidence of response to therapy with > 90% of tumor remaining [32]; PR, progesterone receptor; SC, scattered; TAC3, docetaxel, doxorubicin, and
cyclophosphamide.

algorithm which has been described in detail elsewhere
[27-30].
Image analysis

Regions of interest (ROIs) were determined for each set of
permittivity and conductivity images at 1,300 MHz which
proved to be the most reliable and highest resolution
images obtained over all patients and examination dates.
Each ROI was selected at one array position based on
knowledge of the central tumor location from information
provided by the attending oncologist with support from
the study radiologists - both in terms of distance from the
chestwall and spatially within the anatomically coronal
plane. Given that breast positioning from examination to
examination was not identical, and that the breast may
change size over the course of therapy due to structural
and compositional changes from treatment, care was exercised to align the ROI plane between sessions. Similarlysized regions were also applied to reduce the comparison
bias between examinations. The same process was performed to define representative non-tumor tissue ROIs for
generating the background metrics used in the analysis. A
graphical user interface was used to identify each zone and
compute the microwave property averages and associated
standard deviations automatically. Figure 1 shows a representative example of a set of breast images used in the
analysis. The ROIs resulted from planes where the tumors
were dominant in the permittivity and conductivity
images. The background zones were selected from planes
farther away from the dominant tumor cross-sections to
minimize any influences of the elevated tumor properties
on the background estimate that can occur from the
smoothing characteristics of the image regularization

process. In addition, because the normal sections of the
breast contain zones of adipose and fibroglandular tissue,
and the properties of the latter are known to vary considerably, we chose background regions consisting primarily
of adipose tissue (as demonstrated by their very low property values) as a stable and consistent baseline for the
duration of the study [31].
Clinical (MR) imaging

MR breast images were acquired in a 1.5T scanner (GE
Signa, GE Healthcare, Waukesha, WI, USA) for standard
clinical indications or a 3T (Philips Achieva, Philips
Healthcare, Andover, MA, USA) system for research studies. Dedicated breast coils were used with sub-millimeter
in-plane resolution and slice thicknesses of < 3 mm (T1weighted) and < 5 mm (T2-weighted). T1 and T2 scans
provided detailed maps of tissue structure which were
used to differentiate breast tissue types. Three dimensional
gradient echo T1-weighted sequences with chemical fat
suppression were performed prior to and at one to two
minute intervals following the injection of a bolus of contrast (Gadodiamide, Omniscan, GE Healthcare) of 0.1
mmol per kilogram of body weight to identify suspicious
enhancement foci. The first post-contrast scan was
initiated 40 seconds after injection. Subtraction images
were generated with the pre-contrast gradient echo T1
image as the reference to assess the Gd washout behavior.
Pathology

Standard surgical pathology analysis of the excised tissues
was used to assess subject outcomes. The subjects compared in this pilot study underwent surgical mastectomy
[32]. The mastectomy specimens were sectioned fresh,
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Figure 1 1300 MHz permittivity (top row) and conductivity (bottom row) images for all 7 planes. Breast perimeter, and tumor ROI and
background zones used in the analysis are indicated. ROI, region of interest.

medial to lateral, in the sagittal plane. Each tissue slice
was examined grossly and photographed for image correlation. Areas of treatment response, residual tumor and
normal breast were sampled and processed for microscopic analysis per standard laboratory protocols (formalin fixation, dehydration, paraffin-embedding, 4 micron
sectioning and H & E stain). Complete pathologic
response (pCR) was defined as a complete absence pathologically of cancer in the breast after extensive sampling.

Results and discussion
Case I - complete response

The first patient had a locally advanced cancer on the right
side. At diagnosis, the right breast mammogram showed
linear and pleomorphic micro-calcifications in a segmental
distribution over the lower-central and entire lower-inner
gradient while also demonstrating skin thickening in overlying zones. The tumor measured 6.5 × 3.7 × 7.1 cm by

MRI. Biopsy demonstrated an intermediate grade invasive
ductal carcinoma with a component of ductal carcinoma
in situ (DCIS), estrogen receptor positive (ER(+)), progesterone receptor negative (PR(-)), human epidermal growth
factor receptor-2 (HER-2)/neu(+) (HER-2:CEP-17 14.2).
The patient was treated with four cycles of doxorubicin
and cyclophosphamide, followed by four cycles of weekly
paclitaxel and traztuzumab (PT) and then underwent
modified radical right mastectomy. Surgical pathology
revealed a complete pathologic response.
Contrast-enhanced MRI was performed prior to treatment, at day 85, and at completion of neoadjuvant therapy prior to surgery. Figure 2a shows a sequence of
corresponding sagittal images of the right breast prior to
treatment consisting of (i) a baseline T2 sequence, (ii) a
gadolinium enhancement image and (iii) a baseline subtraction image. The dominant feature reveals a large dispersed tumor in the lower portion of the breast extending
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Figure 2 Sagittal MR images of the right breast of a patient with a complete pathologic response: (a) images prior to therapy and (b)
at day 85. For each set, (i) is a T2-weighted image, (ii) is a contrast-enhanced image from a SPGR sequence, and (iii) is a subtraction image
between (ii) and a pre-contrast baseline, respectively. MR, magnetic resonance; SPGR, spoiled gradient recalled.

from the nipple to the chestwall. Enhancement of lymph
nodes in the upper right corner of the images is also evident. The contrast enhanced image exhibits significant
skin thickening around most of the breast, but especially
near the nipple. In addition, the T2 image shows substantial edema (because it does not enhance in the subtraction
image) under the skin in the regions near the nipple
which is due to the dermal lymphatics. The corresponding images at day 85 (Figure 2b) show enhancement in
the same span from the nipple to the chestwall but at a
reduced level, indicative of response at this intermediate
point during treatment. By this time, the skin has also
thinned considerably with a corresponding reduction in
edema.
MT was conducted prior to the start of therapy, five
other times during treatment and just prior to surgery.
Figure 3 shows the recovered, en face permittivity and
conductivity images for anatomically coronal planes 5, 6
and 7 (Plane 1 is closest to the chestwall and subsequent

planes move away in 1 cm increments) for (a) the left
(contralateral) breast before chemotherapy, (b) the right
(ipsilateral) breast before chemotherapy, (c) the right
breast at day 44, and (d) the right breast after therapy.
For the left breast, the tissue boundary is readily evident
and decreases in size from plane 5 to 7 as expected.
Both permittivity (εr) and conductivity (s) images show
the breast exhibiting relative low values with a somewhat elevated central region most likely associated with
higher water-content fibroglandular tissue [31].
For the right (diseased) breast images prior to treatment, the coronal perimeters are more uneven with elevated property zones in the lower quadrants and
increased properties on the breast boundary likely corresponding to the tumor, skin thickening and edema
appearing in the MRI, respectively. At day 44 (Figure 3c)
the baseline MT images have changed significantly and
show: (1) improved delineation of the breast boundary,
(2) diminished tumor size and property intensity, and
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Figure 3 1300 MHz microwave tomographic images. Imaging planes five to seven are shown corresponding to the three closest planes to
the nipple with the permittivity on the top row and conductivity on the bottom row. (a) Left (contralateral) breast prior to treatment, (b) right
(ipsilateral) breast prior to treatment, (c) right breast 44 days into treatment, and (d) right breast immediately prior to surgery.

(3) reduced property intensity along the lower breast
edge. All three findings appear to correspond well with
the clinical tumor size reduction, skin thinning and

decrease in subdermal edema. At the end of treatment,
the breast outline is even more regular than in the previous images, the recovered tumor enhancement is
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further reduced and no enhancement appears near the
breast perimeter.
A significant reduction in the recovered dielectric
properties occurred within the tumor region as treatment progressed. The post-surgical pathological evaluation confirmed a complete response. Larger areas of
soft, grey-white tissue appear where the tumor had been
treated. Microscopic analysis showed no signs of viable
tumor with only stromal scarring, macrophages and
inflammation in the treated areas. Dielectric probe measurements in pathology revealed that the treated tumor
properties have not reverted back to values corresponding to fibroglandular zones in the contralateral breast as
expected since the treated area is no longer representative of normal breast tissue.
Figure 4 summarizes the 1,300 MHz ROI:background
property ratios as a function of time for all MT examinations during treatment of this patient. The permittivity ratio decreased somewhat unevenly and had a total
reduction of 38% from the start to end of treatment.
The εr value did not drop below 89% of its initial level
until the day 114 examination. The conductivity ratio
exhibited a more dramatic and earlier reduction - 56%
decrease after 23 days and 82% decrease after treatment
completion, respectively, which is consistent with our
previous clinical results that indicated the conductivity
images are significantly more sensitive to the presence
of tumor than their permittivity partners.
Case II - non-responder

The second case was a woman who presented with locally
advanced and metastatic breast cancer. Initial MRI showed
a 4 × 2.5 × 4 cm irregular complex cystic mass in the
upper outer quadrant of the left breast. Two smaller (1 cm)
lesions were noted superior and anterior to the primary
tumor. Core needle biopsy of the primary tumor
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demonstrated a high grade invasive ductal carcinoma with
angiolymphatic invasion, weakly ER(+), PR(-), HER-2/neu
(-) (HER-2:CEP-17 1.09). Left axillary lymph node biopsy
was positive for metastatic disease. The patient was treated
with four cycles of single agent weekly TOCOSOL paclitaxel (Eagle Pharmaceuticals, Belgrade, Serbia), followed by
left simple mastectomy. Surgical pathology revealed a partial pathologic response with the treatment effect estimated
as comprising > 50% but < 90% of the original tumor.
MR images were obtained throughout neoadjuvant
treatment and two weeks prior to mastectomy (day 85).
Figure 5a shows a sequence of corresponding sagittal
images of the left breast prior to treatment with (i) a T2
sequence, (ii) a gadolinium enhancement image and (iii)
a baseline subtraction image. The pre-treatment MR
images presented a large mass with in-plane gadolinium-enhancing dimensions of 4.7 × 2.6 cm and a secondary satellite (anterior) enhancement. A large water
filled cavity (seroma resulting from an earlier biopsy)
appeared directly adjacent to the tumor. Figure 5b
shows the corresponding images for day 52 which exhibit a more pronounced tumor adjacent to the seroma
(visible as a dark region in the subtraction image) with
distinct spiculations radiating from the center. This MR
set showed an enhancing zone of 3.5 × 4.3 cm in a similar
area with possible progression anteriorly. The washout
kinetics were similar to those of the first examination.
A later study at day 85 indicates that the satellite lesion
became more active in terms of its enhancement/rapid
washout rate suggesting tumor progression in this area. By
the time of the last MR (not shown), the gadoliniumenhancing zone had grown to 5.4 × 3.9 cm and showed
washout kinetics indicative of malignant progression. This
study suggested that the larger primary mass had merged
with the secondary satellite focus evident in the first
examination.

Figure 4 Summary of the permittivity and conductivity region of interest (ROI) analysis for the MT imaging sessions from the start of
treatment until just prior to surgery. MT, microwave tomography.
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Figure 5 Sagittal MR images of the left breast of a patient with pathologic non-response: (a) images prior to therapy, (b) images on
day 52, and (c) images prior to surgery. For each set, (i) is a T2-weighted image, (ii) is a contrast-enhanced image using an SPGR sequence,
and (iii) is a subtraction image between (ii) and a baseline, respectively. MR, magnetic resonance; SPGR, spoiled gradient recalled.

MT was conducted prior to the start of therapy, at
five times during treatment and just prior to surgery.
Figure 6 shows the reconstructed images for planes two

to six (1.0 cm increments) for (a) the right breast at the
start of chemotherapy and for the left breast at (b) the
start of chemotherapy, (c) day 28, and (d) just prior to
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Figure 6 1300 MHz microwave tomographic images. Imaging planes two to six are shown corresponding to the five closest planes to the
nipple with the permittivity on the top row and conductivity on the bottom row. (a) Right (contralateral) breast prior to treatment, (b) left
(ipsilateral) breast prior to treatment, (c) left breast 57 days into treatment, and (d) left breast immediately prior to surgery.

surgery. The right breast images present relatively
homogeneous dielectric properties in all planes, except
for an elevated zone in the lower central to lower-right

quadrant which probably corresponds to a concentration
of fibroglandular tissue. As is typical with these images,
the outline of the breast is evident and decreases in
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diameter as the planes progress towards the nipple.
Some artifacts appear in plane two (closer to the chestwall), especially an unevenness in the breast permittivity
perimeter and a slightly elevated zone in the upper-left
edge of the conductivity image. These artifacts are fairly
common occurrences in our images, especially for larger
breasts and those with very high property contrast with
the coupling bath, and have been noted previously in
Meaney et al. [26,33].
For the left breast images, the outer boundaries appear
more disrupted than in the contralateral breast and significant internal zones of both permittivity and conductivity
enhancement are evident. Enhancement occurs in the
upper-central to upper-right regions in planes two to four
of the permittivity and planes two to five of the conductivity images at the first two imaging dates (pre-chemotherapy
and day 52). This visibility over multiple planes is indicative
of a large tumor. The enhanced area in plane four of the
permittivity image from the second examination is much
more intense (higher values) than the corresponding plane
for the first examination and appears to corroborate the
MR observation that the tumor was growing. The microwave images obtained from the last examination suggest
that the tumor has expanded significantly in size with the
appearance of substantial enhancement in both planes five
and six. The level of enhancement in the conductivity
images has also increased correspondingly. These results
correlate well with the clinical observations that the tumor
spread anteriorly towards a satellite location and that the
primary and secondary tumors had merged by the time of
surgery.
Figure 7 summarizes the ROI:background ratios for both
the permittivity and conductivity images as a function of
time. In this case, the permittivity ROI:background values
remain relatively constant but then increase dramatically
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towards the end of treatment. The corresponding conductivity ratios are much more uneven with sharp increases at
day 2 and day 28. The uneven behavior may be due in
part to the fact that the tumor did appear to partially
respond in some areas (for example, during the first 21
days) but then expanded towards the anterior portion of
the breast. Nonetheless, the ROI:background values did
not decrease appreciably at any extended duration during
treatment and are consistent with the pathological determination of non-response.
Contralateral example

For comparison, we also collected data from the contralateral breast when possible (that is, examination timepermitting, patient not feeling ill, and so on) and show
example images from planes one to four for Patient #8 at
the first date, day 33 and day 62 after the start of treatment (Figure 8). In these images, the permittivity and conductivity outlines of the breast are evident in terms of a
property gradient with the background coupling fluid. As
the images progress from plane one to four, the overall
breast diameter decreases - a feature that is more obvious
in the conductivity results. In the permittivity images, an
annulus of lower property tissue surrounds a more elevated zone in each of the four planes. This central region
contains more fibroglandular tissue for which higher permittivity properties are expected relative to the surrounding adipose tissue. In the conductivity images, the first two
planes also show elevated property zones towards the
lower right quadrant; however, they begin to disappear in
planes three and four as the overall size of the breast
cross-section shrinks, and the increased fibroglandular
tissue properties begin to blur with the higher properties
of the surrounding coupling liquid. The images for all
three examination dates are similar and do not suggest

Figure 7 Summary of the permittivity and conductivity region of interest (ROI) analysis for the MT imaging sessions from the start of
treatment until just prior to surgery. MT, microwave tomography.
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Figure 8 1300 MHz microwave tomographic images of the contralateral breast for Patient 8. Imaging planes one to four are shown
corresponding to the four closest planes to the chest wall with the permittivity on the top and conductivity on the bottom row, respectively.
(a) Prior to treatment, (b) day 33, and (c) day 62.

significant changes other than from minor shifting of the
position of the breast within the field of view.
We were not always able to collect as much data from
the contralateral breast as for the ipsilateral (diseased)

side for multiple reasons: (a) several patients had ports
inserted in the contralateral breast for drug infusion
that precluded imaging, (b) multiple experimental imaging modalities were involved in the study, so the total
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examination time allotted to MT was limited, and (c)
some patients were simply feeling too ill to participate
in more than a single-sided breast examination.
Summary of the eight patient study

We studied the normalized ROI:background outcome
ratios with respect to baseline as a function of time after
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initiation of treatment for all eight subjects (four complete response, four incomplete (non)-response). Figure 9
shows a summary of the data points for all eight patients.
We applied a linear mixed model with random intercept
(subject) and slope effects to analyze both permittivity
and conductivity separately. We used the restricted maximum likelihood (REML) method to estimate coefficients.

Figure 9 Summary of the permittivity and conductivity region of interest (ROI) analysis for the MT imaging sessions for all patients
during treatment. MT, microwave tomography.
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Covariates included in the model were group (1 = complete responder and 0 = non-responder), days from baseline, and interactions between group and days from
baseline. Days from baseline was treated as a continuous
variable. SAS 9.2 (SAS Institute Inc., Cary, NC, USA) was
used to conduct all statistical analyses. Two-side significance level was set at 5%. In order to ensure that the
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estimated upper and lower value bounds be positive, all
statistical analyses were based on the natural log transformed normalized outcome and then transformed back
for figure presentation. Figures 10a and 10b show the
permittivity and conductivity plots from the fitted analysis curves for the complete-responder and incomplete
(non)-responder groups.

Figure 10 Fractional change summary for all patients for the 1300 MHz permittivity and conductivity ROI:Background ratios over the
full course of treatments. Dashed lines indicate the 95% confidence intervals for the Responder (in blue) and Non-responder (in red) curves
for permittivity in (a) and conductivity in (b). ROI, region of interest.
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The mean of the normalized permittivity ROI:background ratio for complete responders was not significantly different from that for incomplete-responders (Pvalue = 0.68) over the full treatment intervals. However,
the corresponding normalized mean conductivity for the
complete responders was significantly different from
that for non-responders (P-value = 0.004). There were
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no significant time or interaction effects for either
dielectric property in the study. We investigated whether
other covariates, including body mass index (BMI), age
and breast density (we grouped fatty and scattered density breasts into a single low density category, and heterogeneously dense and extremely dense breasts into
one high density group, respectively) influenced the

Figure 11 Fractional change summary for all patients for the 1300 MHz permittivity and conductivity ROI:Background ratios over the
full course of treatment with outliers removed. Dashed lines indicate the 95% confidence intervals for the Responder (in blue) and Nonresponder (in red) curves for permittivity in (a) and conductivity in (b). ROI, region of interest.
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results. For both permittivity and conductivity, the effect
of these factors was not significant (P-values for the
three variables were 0.84, 0.36 and 0.32 for permittivity,
respectively, and 0.41, 0.58 and 0.07 for conductivity,
respectively). We also analyzed the interaction between
the group and days from baseline variables and found
no association (P-values of 0.14 and 0.28 for the permittivity and conductivity, respectively). These results are
consistent with our prior experience in which conductivity was found to have a higher level of correlation
with tumor presence than the corresponding permittivity values and would be expected to be the superior
measure of tumor progression/regression [25]. In addition, the normalized conductivity measure had a high
level of association with complete tumor response at 30
days (P-value = 0.002) - a finding that could be clinically
important because it would provide valuable early-stage
information on tumor progression and whether the current therapy regimen should be continued or modified.
Finally, we assessed whether outliers may have influenced these results. After removing the data point from
Patient #2 on day 104 for both permittivity and conductivity, we compared outcomes between the two groups
with the same statistical model described above. In this
instance, significant differences resulted between the
responder and non-responder groups for both permittivity and conductivity; the P-values were 0.0024 and
0.0019, respectively (Figures 11a and 11b). This outcome
confirms our hypothesis that the conductivity is statistically significant; however, the permittivity becomes statistically significant when the data point is removed.
While likely caused by the fact that the study is relatively small, the property trajectories in the two groups
(responders versus non-responders) can be very different. For the complete responders, tumor is destroyed in
all instances and, based on limited data from dielectric
probe studies, tissue electrical properties trend downwards after successful treatment. However, the tissue
characteristics of non-responders are likely to be more
variable because in some cases the tissue properties may
stay the same or be similar whereas in others tumor
progression is likely to yield even higher dielectric properties over time. As a result, the data point removed
from Patient #2 may not be an actual outlier, but rather
indicative of a more complex tissue behavior that the
non-response might be causing.

Conclusions
We have conducted a preliminary investigation using
MT to monitor the progression of breast cancer
response to neoadjuvant chemotherapy. Early indications
show that the images are repeatable and sensitive to
drug-induced breast changes. Of particular interest is
the response at one month after the start of treatment

Page 15 of 16

where analysis of the conductivity in the ROI was found
to distinguish statistically between the complete and
incomplete (non)-responding patient groups. Early prediction of treatment success (or lack thereof) could provide useful information to medical oncologists with
respect to altering treatment when a patient is not
responding to the initial therapy. MT could be performed at numerous stages during treatment at relatively low cost and may be particularly attractive for this
type of longitudinal monitoring where the conventional
imaging alternatives (for example, MR; FDG PET) are
less feasible because of cost and inconvenience.
Abbreviations
ER: estrogen receptor; FDG PET: fluorodeoxyglucose positron emission
tomography; H & E: hematoxylin and eosin; HER2: human epidermal growth
factor receptor-2; MT: microwave tomography; NCT: neoadjuvant
chemotherapy; PR: progesterone receptor; PT: paclitaxel and traztuzumab;
ROIs: regions of interest.
Authors’ contributions
PM supervised all aspects of the microwave tomography data acquisition,
image reconstruction and data analysis and contributed to the manuscript
preparation. PK designed the study, recruited volunteers, supervised the
patients’ treatment protocols and contributed to the manuscript preparation.
LM coordinated the oncological aspects of the study and contributed to the
manuscript preparation. MC interpreted the conventional modality images
including MR. SP supervised the interpretation of all conventional modality
images including MR. WW supervised the histopathologic preparation and
assessment of the breast tissue samples after mastectomy. GS participated in
study design and contributed patients to the study. RD interpreted the
conventional modality images including MR. TT designed and supervised
the statistical analysis. ZL performed the statistical analysis. SG organized all
clinical and microwave data and performed the microwave image
reconstructions. MF coordinated the multi-modality imaging sessions and
designed and optimized the data acquisition software. TZ performed the
microwave examinations, designed some hardware and was involved in the
image reconstruction process. NE performed the microwave examinations,
designed some microwave electronics and was involved in the clinical data
organization. KD supervised all aspects of the microwave tomography and
coordination with the Radiology, Oncology and Pathology Departments,
assisted in the study design and contributed to the manuscript preparation.
All authors read and approved the final manuscript.
Competing interests
Drs. Meaney and Paulsen declare that they are co-founders of Microwave
Imaging System Technologies, Inc. (MIST) which does have a financial
interest in developing microwave breast imaging equipment. However, MIST
did not sponsor this effort related to microwave tomography for
chemotherapy monitoring. The remaining authors declare that they have no
competing interests.
Acknowledgements
This work was sponsored by National Institutes of Health/National Cancer
Institute grant # PO1-CA080139.
Author details
1
Thayer School of Engineering, Dartmouth College, 14 Engineering Dr.,
Hanover, NH 03755, USA. 2Oncology, Dartmouth-Hitchcock Medical Center, 1
Medical Center Dr., Lebanon, NH 03756, USA. 3Radiology, DartmouthHitchcock Medical Center, 1 Medical Center Dr., Lebanon, NH 03756, USA.
4
Pathology, Dartmouth-Hitchcock Medical Center, 1 Medical Center Dr.,
Lebanon, NH 03756, USA. 5Biostatistics Shared Resource, DartmouthHitchcock Medical Center, 1 Medical Center Dr., Lebanon, NH 03756, USA.
6
Radiology, Geisel School of Medicine, Dartmouth College, 74 College St.,
Hanover, NH 03755, USA. 760 Cobb Hill Rd., Hartland, VT 05048, USA.

Meaney et al. Breast Cancer Research 2013, 15:R35
http://breast-cancer-research.com/content/15/2/R35

8
Engineering, Kuang-Chi Institute of Advanced Technology, 29 Nanhuan Rd.,
Shenzhen, Guangdong, 518057, China.

Received: 13 July 2012 Revised: 9 January 2013
Accepted: 8 March 2013 Published: 24 April 2013
References
1. Esserman L: Neoadjuvant chemotherapy for primary breast cancer:
lessons learned and opportunities to optimize therapy. Ann Surg Oncol
2004, 11:3S-8S.
2. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG,
Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL,
Lees AW, Dimitrov NV: Effect of preoperative chemotherapy on localregional disease in women with operable breast cancer: findings from
National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol
1997, 15:2483-2493.
3. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS,
Rugo HS, Hwang ES, Ewing CA, Hylton NM: MRI measurements of breast
tumor volume predict response to neoadjuvant chemotherapy and
recurrence-free survival. Am J Roentgenol 2005, 184:1774-1781.
4. American College of Radiology Imaging Network: ACRIN Protocol 6657:
contrast-enhanced breast MRI for evaluation of patients undergoing
neoadjuvant treatment for locally-advanced breast cancer. 2007 [http://
www.acrin.org/TabID/147/Default.aspx].
5. Rousseau C, Devillers A, Sagan C, Ferrer L, Bridji B, Campion L, Ricaud M,
Bourbouloux E, Doutriaux I, Clouet M, Berton-Rigaud D, Bouriel C,
Delecroix V, Garin E, Rouquette S, Resche I, Kerbrat P, Chatal JF,
Campone M: Monitoring of early response to neoadjuvant
chemotherapy in stage II and III breast cancer by [18F]
fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006,
24:5366-5372.
6. Manton DJ, Chaturvedi A, Hubbard A, Lind MJ, Lowry M, Maraveyas A,
Pickles MD, Tozer DJ, Turnbull LW: Neoadjuvant chemotherapy in breast
cancer: early response prediction with quantitative MR imaging and
spectroscopy. Br J Cancer 2006, 94:427-435.
7. Tripathy D, Jiang L, Rao N, McColl R, Xie X, Weatherall P, Ding L, Mason R:
Blood oxygen level dependent (BOLD) contrast MRI and breast cancer
chemotherapy response. Proc Am Soc Clin Oncol Meet 2006.
8. Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT,
Emory TH, Tuttle TM, Yee D, Garwood M: Neoadjuvant chemotherapy of
locally advanced breast cancer: predicting response with in vivo (1)H
MR spectroscopy–a pilot study at 4 T. Radiol 2004, 233:424-431.
9. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Molinterni A, Terenziani M,
Zambetti M: Primary chemotherapy in operable breast cancer: eight
years experience at the Milan Cancer Institute. J Clin Oncol 1998,
16:93-100.
10. Huber S, Medl M, Helbich T, Taucher S, Wagner T, Rudas M, Zuna I,
Delorme S: Locally advanced breast carcinoma: computer assisted
semiquantitative analysis of color Doppler ultrasonography in the
evaluation of tumor response to neoadjuvant chemotherapy (work in
progress). J Ultrasound Med 2000, 19:601-607.
11. Cerussi A, Hsiang D, Shah N, Mehta R, Durkin A, Butler J, Tromberg BJ:
Predicting response to breast cancer neoadjuvant chemotherapy using
diffuse optical spectroscopy. Proc Natl Acad Sci USA 2007, 104:4014-4019.
12. Jiang S, Pogue BW, Carpenter CM, Poplack SP, Wells WA, Kogel CA,
Forero JA, Muffly LS, Schwartz GN, Paulsen KD, Kaufman PA: Evaluation of
breast tumor response to neoadjuvant chemotherapy with tomographic
diffuse optical spectroscopy: case studies of tumor region-of-interest
changes. Radiol 2009, 252:551-560.
13. Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Lawton TJ,
Barlow WE, Schubert EK, Mankoff DA: Residual tumor uptake of [99mTc]sestamibi after neoadjuvant chemotherapy for locally advanced breast
carcinoma predicts survival. Cancer 2005, 103:680-688.
14. Craddock IJ, Nilavalan R, Leendertz J, Preece A, Benjamin R: Experimental
investigation of real aperture synthetically organised radar for breast
cancer detection. Dig IEEE Antennas Propag Soc Int Symp 2005, 1B:179-182.
15. Fear EC, Li X, Hagness SC, Stuchly MA: Confocal microwave imaging for
breast cancer detection: localization of tumors in three dimensions. IEEE
Trans Biomed Eng 2002, 49:812-822.
16. Yun X, Fear EC, Johnston RH: Compact antenna for radar-based breast
cancer detection. IEEE Trans Antennas Propag 2005, 53:2374-2380.

Page 16 of 16

17. Xu L, Bond EJ, van Veen BD, Hagness SC: An overview of ultra-wideband
microwave imaging via space-time beamforming for early-stage breast
cancer detection. IEEE Antenn Propag Mag 2005, 47:19-34.
18. Davis SK, Tandradinata H, Hagness SC, van Veen BD: Ultrawideband
microwave breast cancer detection: a detection-theoretic approach
using the generalized likelihood ratio test. IEEE Trans Biomed Eng 2005,
52:1237-1250.
19. Bardati F, Iudicello S, Tognolatti P: A Microwave radiometer for diagnosis
of breast malignancy. Int Conf Electromagnetics Adv App 2007, 1014-1017.
20. Carr KL: Microwave radiometry: its importance to the detection of
cancer. IEEE Trans Microwave Theory Tech 1989, 37:1862-1869.
21. Carr KL, Cevasco P, Dunlea P, Shaeffer J: Radiometric sensing: an adjuvant
to mammography to determine breast biopsy. IEEE MTT-S Int Microw
Symp Dig 2000, 2:929-932.
22. Ciocan R, Jiang H: Model-based microwave image reconstruction:
simulations and experiments. Med Phys 2004, 31:3231-3241.
23. Meaney PM, Fanning MW, Li D, Poplack SP, Paulsen KD: A clinical
prototype for active microwave imaging of the breast. IEEE Trans
Microwave Theory Tech 2000, 48:1841-1853.
24. Poplack SP, Paulsen KD, Hartov A, Meaney PM, Pogue B, Tosteson T,
Grove M, Soho S, Wells W: Electromagnetic breast imaging - average
tissue property values in women with negative clinical findings. Radiol
2004, 231:571-580.
25. Poplack SP, Paulsen KD, Hartov A, Meaney PM, Pogue B, Tosteson T,
Grove M, Soho S, Wells W: Electromagnetic breast imaging - pilot results
in women with abnormal mammography. Radiol 2007, 243:350-359.
26. Meaney PM, Fanning MW, Raynolds T, Fox CJ, Fang Q, Kogel CA,
Poplack SP, Paulsen KD: Initial clinical experience with microwave breast
imaging in women with normal mammography. Acad Radiol 2007,
14:207-218.
27. Fang Q, Meaney PM, Paulsen KD: Microwave image reconstruction of
tissue property dispersion characteristics utilizing multiple frequency
information. IEEE Trans Microwave Theory Tech 2004, 52:1866-1875.
28. Paulsen KD, Meaney PM: Compensation for nonactive array element
effects in a microwave imaging system: part I - forward solution vs.
measured data comparison. IEEE Trans Med Imag 1999, 18:496-507.
29. Paulsen KD, Meaney PM, Moskowitz MJ, Sullivan JM Jr: A dual mesh
scheme for finite element based reconstruction algorithms. IEEE Trans
Med Imag 1995, 14:504-514.
30. Meaney PM, Paulsen KD, Ryan TP: Two-dimensional hybrid element image
reconstruction for TM illumination. IEEE Trans Antennas Propag 1995,
43:239-247.
31. Lazebnik M, Popovic D, McCartney L, Watkins CB, Lindstrom MJ, Harter J,
Sewall S, Ogilvie T, Magliocco A, Breslin TM, Temple W, Mew D, Booske JH,
Okoniewski M, Hagness SC: A large-scale study of the ultrawideband
microwave dielectric properties of normal, benign and malignant breast
tissues obtained from cancer surgeries. Phys Med Biol 2007, 52:6093-6115.
32. Pinder SE, Provenzano E, Earl H, Ellis IO: Laboratory handling and histology
reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology 2007, 50:409-417.
33. Fox CJ, Meaney PM, Shubitidze F, Potwin L, Paulsen KD: Characterization of
a monopole antenna in a lossy medium for microwave breast
computed tomography. Int J Ant and Propag 2008, 2008:580782.
doi:10.1186/bcr3418
Cite this article as: Meaney et al.: Microwave imaging for neoadjuvant
chemotherapy monitoring: initial clinical experience. Breast Cancer
Research 2013 15:R35.

